Cancer Research in Switzerland - Krebsliga Schweiz

More documents

Recommendations

Info

164 Nadal David | Is endemic Burkitt’s lymphoma really promoted by chronic innate immunity triggering by malaria infection? (KLS 02375-02-2009) Duration: 01.10.2009 – 01.10.2011 Endemic Burkitt’s lymphoma (BL) is a type of lymph node cancer in Africa. The cancer cells harbour Epstein-Barr virus (EBV), which infects over 90 % of children for a lifetime. Malaria is thought to contribute to the formation of this cancer type. We have shown that stimulation of the innate immunity, as malaria does, pushes EBV into a form that enables lymphocytes to continuously proliferate. We will study the impact of immune stimulation on the preservation of EBV’s form, leading to survival and unrestricted proliferation of cells. Newly gained insights into the interaction between chronic stimulation of the innate immunity and the behaviour of EBV-infected cells towards cancer will hopefully allow the engineering of novel modalities for prevention and treatment of EBV-harbouring lymphomas. Project coordinator Prof. Dr. David Nadal Abteilung Infektiologie und Spitalhygiene Kinderspital Zürich Universitäts-Kinderkliniken Steinwiesstrasse 75 CH-8032 Zürich Phone +41 (0)44 266 72 50 Fax +41 (0)44 266 80 72 david.nadal@kispi.uzh.ch Niggli Felix | Constitution of a national study centre for the European acute lymphoblastic leukaemia trial (AIEOP-BFM ALL 2009) on behalf of the Swiss Paediatric Oncology Group (BFM-CH) (KLS 02578-02-2010) Duration: 01.06.2010 – 01.06.2013 Acute lymphoblastic leukaemia (ALL) is the most common malignancy of childhood. Remarkable progress has been made in the past decades. Combination treatment with intensive multi-agent chemotherapeutic regimens, adapted to biological factors like response to treatment, cytogenetic changes in leukaemic cells and minimal residual disease after initial treatment phase has raised the cure rate of the disease to over 80 %. However, treatment burden is still considerable. An international consortium established a new treatment protocol (AIEOP-BFM ALL 2009 trial) with risk adapted treatment application, taking also into account early response assessment. Within the Swiss Paediatric Oncology Group we will establish a national study centre for ALL to coordinate relevant diagnostic procedures and to perform reference investigation, data collection and coordination of research. We hope to further improve the survival rate for childhood ALL and to decrease side effects, at least in subgroups of patients. Project coordinator Prof. Dr. Felix Niggli Onkologielabor Kinderspital Zürich Universitäts-Kinderkliniken Steinwiesstrasse 75 CH-8032 Zürich Phone +41 (0)44 266 71 11 felix.niggli.@kispi.uzh.ch Ozsahin Hulya | SIOPEL International Childhood Liver Tumour Strategy Group – a comprehensive research program and a randomized trial for standard risk hepatoblastoma (KLS 02656-08-2010) Duration: 01.10.2010 – 01.10.2013 SIOPEL (Société internationale d’oncologie pédiatrique – Epithelial Liver Tumour Study Group) is a trials group for research on the diagnosis, treatment and long-term outcome of childhood hepatoblastoma (HB) and hepatocellular carcinoma. These cancers are extremely rare, with about 1.5 cases per million per year. The Swiss Paediatric Oncology Group (SPOG) has participated in SIOPEL trials 1– 4 and is activating SIOPEL 6 in Switzerland. SIOPEL 6 is a multi-centre randomised phase III trial of the efficacy of sodium thiosulphate in reducing hearing loss with cisplatin chemotherapy for standard risk HB. The continued participation of SPOG in SIOPEL activities and research will result in optimal treatment of children with HB. Project coordinator Prof. Dr Hulya Ozsahin Unité d’onco-hématologie pédiatrique Hôpitaux universitaires de Genève (HUG) 6, rue Willy-Donzé CH-1211 Genève 14 Phone +41 (0)22 382 46 20 Fax +41 (0)22 382 47 20 ayse.h.ozsahin@hcuge.ch Pabst Thomas | Transcriptional dysregulation of the myeloid key transcription factor CEBPA in human acute myeloid leukemia (KLS 02520-02-2010) Duration: 01.07.2010 – 01.07.2013 Despite intensive chemotherapy, more than 50 % of patients with acute myeloid leukemia (AML) still die of the disease. To improve the treatment of patients with AML, novel innovative concepts are needed. The concept of differentiation therapy offers a possible approach. The block in normal differentiation of white blood cells is characteristic for AML cells. Importantly, each step during differentiation of normal white blood cells is regulated by only a handful of transcription factors. In particular, the transcription factor CEBPA plays a key role in this process. If CEBPA function is deficient, no mature granulocytes are observed, and this leads to an accumulation of leukaemic blasts. In this project, we analyze how CEBPA protein expression is regulated in leukaemic cells. Further, we aim to elucidate how CEBPA controls a new class of regulating molecules called microRNAs. Through specific reconstitution of CEBPA function, we intend finally to develop a novel therapeutic approach for patients with AML. Project coordinator Prof. Dr. Thomas Pabst Institut für medizinische Onkologie Universität Bern Inselspital CH-3010 Bern Phone +41 (0)31 632 41 15 Fax +41 (0)31 632 41 19 thomas.pabst@insel.ch
Petignat Patrick | Self-sampling for HPV in women who do not undergo routine cervical cancer screening: A randomized trial (KFS 02691-08-2010) Duration: 01.09.2011– 01.09.2013 In Switzerland, 250 to 300 women are diagnosed with cervical cancer each year, and 100 die of the disease. Some 30–40 % of Swiss women do not have cervical cancer screening and are therefore at higher risk of developing cervical cancer. The study will include 1,100 women aged 25 to 69 years who have not participated in routine screening in the last three years. They will be invited to the screening procedure, a Pap smear (control group), or HPV self-sampling (study group). In the latter group, women will be able to take the sample themselves at home, using a kit that will be sent to them. The results of this study could provide women not screened by Pap tests with a simple alternative form of screening. This could overcome barriers to presentation for screening, such as difficulty in reaching a doctor, reluctance to undergo gynaecological examination and cost. Interviews will be conducted in order to gain a better understanding of the reasons for non-attendance and to gauge the acceptability of self-sampling. Project coordinator Prof. Dr Patrick Petignat Unité d’oncogynécologie chirurgicale Hôpitaux universitaires de Genève (HUG) Boulevard de la Cluse 30 CH-1211 Genève Phone +41 (0)22 382 68 16 patrick.petignat@hcuge.ch Renevey Philippe | Automatic vocal aid system for laryngectomees with improved voice quality (KFS 02681-08-2010) Duration: 01.01.2011– 01.01.2013 Medical rehabilitation techniques allow laryngectomees to partially recover vocal function, but it results in poor voice quality and insufficient speech intensity. The ultimate goal of the project is the improvement of existing speech processing algorithms for laryngectomees, which would increase laryngectomees’ quality of life by improving their communicational abilities. The approach is to further improve and refine the algorithms for speech restoration developed in a previous project. Special attention will be devoted to enhancing the perceived natural characteristics and speaker-specific artefacts. High perceptual performance will be aimed at, such as improving speech quality and intelligibility, through combined state-of-the-art parametric and statistical signal processing methods. The expected result is to obtain a sufficient quality of the restored speech so as to be integrated in a usable system (e. g. vocal aid, improvement of telephone calls, public audience amplification). Project coordinator Dr Philippe Renevey Centre suisse d’électronique et de microtechnique (CSEM) Rue Jaquet-Droz 1 CH-2007 Neuchâtel Phone +41 (0)32 720 55 27 prv@csem.ch Resink Therese | T-cadherin: a functional determinant and early prognostic marker for malignant transformation of squamous cell carcinomas (KFS 02447-08-2009) Duration: 01.01.2010–01.01.2013 Skin cancer is a disease in which cancer cells are found in the outer layers of the skin. It occurs in different forms. Melanoma is highly metastatic and deadly. Basalioma (basal cell carcinoma) and spinalioma (squamous cell carcinoma) are relatively benign, but they occur much more frequently and cause major disfigurement. Whereas basalioma growth is locally restricted, spinalioma can transform into malignant metastatic cancers with fatal results. We want to understand the whys and hows of this transformation, and focus on T-cadherin, a molecule that seems important for integrity of skin. Too much or too little of T-cadherin has been found in many skin diseases, including skin cancers. We are studying tissue from spinalioma patients to see if particular changes in T-cadherin can predict malignant transformation. We use cells isolated from healthy skin and spinalioma to study how changes in T-cadherin affects growth and metastatic potential. Given that Switzerland has one of the highest rates of skin cancers in Europe, our results will aid better identification and treatment of those patients at risk of developing metastatic spinalioma. Project coordinator Prof. Dr. Therese Resink Forschungsgruppe Signaltransduktion Departement Biomedizin Universitätsspital Basel Hebelstrasse 20 CH-4031 Basel Phone +41 (0)61 265 24 22 therese-j.resink@unibas.ch Roth Arnaud | Molecular heterogeneity and prognostic markers in colon cancer by analysis of gene expression and gene mutation data (KFS 02697-08-2010) Duration: 01.01.2011– 01.01.2013 Prognostic markers allowing better determination of which patients operated on for colon cancer could benefit from additional treatment are missing. PETACC-3, a clinical trial in postoperative treatment of colon cancer, enrolled 3,278 patients and collected the pathologic material of 1,564 of them for the study of new molecular prognostic factors. In addition to the ability to validate some already known potential prognostic molecular markers, we performed new tests to insulate mutations of the genome of the tumour and to study their genomic expression. These tests provided us with large sets of data 165
Page 1 and 2:
Cancer Research in Switzerland A pu
Page 3 and 4:
Cancer Research in Switzerland
Page 5 and 6:
Basic biomedical research 55 Cancer
Page 7 and 8:
policy work and was in charge of de
Page 9 and 10:
The main focus of the research fund
Page 11 and 12:
gramme research funding decreased b
Page 13 and 14:
Table 2 Distribution of funds for i
Page 15 and 16:
Funding patient-centred research Pa
Page 17 and 18:
value was not clearly discernible.
Page 19 and 20:
New organization of the Foundation
Page 21 and 22:
The board of the Foundation Cancer
Page 23 and 24:
The president of the Scientific Com
Page 25 and 26:
Prof. Martin Pruschy, PhD Departmen
Page 27 and 28:
Swartz wants to find out how tumour
Page 29 and 30:
The scientific and medical research
Page 31 and 32:
3. The original order/sequence of t
Page 33 and 34:
As a federation, the Cancer League
Page 35 and 36:
List of funded research projects, i
Page 37 and 38:
Zippelius Alfred | 2009: CHF 100,00
Page 39 and 40:
Kridel Robert | 2010: CHF 100,000.-
Page 41 and 42:
Thurgau Cancer League Biotechnologi
Page 43 and 44:
Weller Michael | 2010: CHF 65,828.-
Page 45 and 46:
manageable funding of individual pr
Page 47 and 48:
enhances breast cancer cell motilit
Page 49 and 50:
Rüegg Curzio et al. | Tumor-mediat
Page 51 and 52:
International Clinical Cancer Resea
Page 53 and 54:
in PHIV were shown for Hodgkin’s
Page 55:
Zucca Emanuele et al. | Internation
Page 58 and 59:
56 “hierarchical structure” of
Page 60 and 61:
58 the attempt should be made to st
Page 62 and 63:
60 Gönczy Pierre | KLS 0202402
Page 64 and 65:
62 Romero Pedro | OCS 020110220
Page 66 and 67:
64 Beermann Friedrich | In vivo scr
Page 68 and 69:
66 Christofori Gerhard | Podoplanin
Page 70 and 71:
68 Frei Christian | The function of
Page 72 and 73:
70 cell, this novel mechanism serve
Page 74 and 75:
72 Results The induction of viral p
Page 76 and 77:
74 Hübscher Ulrich | Repair of oxi
Page 78 and 79:
76 Methods and experimental approac
Page 80 and 81:
78 of cMyc and/or NMyc and demo
Page 82 and 83:
80 In summary, this work improves o
Page 84 and 85:
82 Pruschy Martin | Microtubule int
Page 86 and 87:
84 Renner Christoph | Selective inh
Page 88 and 89:
86 Goal Here we build on these obse
Page 90 and 91:
88 by TDG prevents efficient downst
Page 92 and 93:
90 To address these questions, we a
Page 94 and 95:
92 Translational relevance The resu
Page 96 and 97:
94 Grünberg Jürgen | KFS 025460
Page 98 and 99:
96 Tschan Mario P. | KFS 0248608
Page 100 and 101:
98 Boyman Onur | Preclinical testin
Page 102 and 103:
100 Constam Daniel | Role of activi
Page 104 and 105:
102 this study we will examine the
Page 106 and 107:
104 Janscak Pavel | Study of the ro
Page 108 and 109:
106 Müller Anne | The molecular pa
Page 110 and 111:
108 Radtke Freddy | The role of Not
Page 112 and 113:
110 Schär Primo | DNA repair, epig
Page 114 and 115:
112 In this project we will investi
Page 116 and 117: 114
Page 118 and 119: 116 and Research). Other financial
Page 120 and 121: 118 be totally unaffordable for aca
Page 122 and 123: 120 Clinical research List of compl
Page 124 and 125: 122 Hunger Robert E. | OCS 02262-08
Page 126 and 127: 124 Clinical research Presentation
Page 128 and 129: 126 Benhattar Jean | Identification
Page 130 and 131: 128 Bertoni Francesco | Genome-wide
Page 132 and 133: 130 Interpretation ESA treatment in
Page 134 and 135: 132 Our results could pave the way
Page 136 and 137: 134 new drugs that specifically tar
Page 138 and 139: 136 slides in two different concent
Page 140 and 141: 138 Conclusions A strong network of
Page 142 and 143: 140 tions introduced to ARE motifs
Page 144 and 145: 142 Müller Beatrice U. | The maste
Page 146 and 147: 144 A novel method was developed fo
Page 148 and 149: 146 (SAKK 35-98) the Swiss Group fo
Page 150 and 151: 148 Timmermann Beate | Prospective
Page 152 and 153: 150 recurrence of the disease, we a
Page 154 and 155: 152 Zucca Emanuele | A prospective
Page 156 and 157: 154 Heinimann Karl | KFS 02489-08-2
Page 158 and 159: 156 Riggi Nicolò | BIL KFS 02717-0
Page 160 and 161: 158 activity at the single cell lev
Page 162 and 163: 160 Our research projects aim at un
Page 164 and 165: 162 Körner Meike | In vitro evalua
Page 168 and 169: 166 (> 50.000/patient). For their a
Page 170 and 171: 168 Zeller Rolf | Functional analys
Page 172 and 173: 170
Page 174 and 175: 172 area of health services researc
Page 176 and 177: 174 The financing of palliative car
Page 178 and 179: 176 National Strategy for Palliativ
Page 180 and 181: 178 Psychosocial research List of c
Page 182 and 183: 180 Within the patient group, level
Page 184 and 185: 182 Further, the results suggest th
Page 186 and 187: 184 It is in this context that the
Page 188 and 189: 186 Recommendation Female spouses o
Page 190 and 191: 188 Psychosocial research Presentat
Page 192 and 193: 190 rates communication skills rema
Page 195 and 196: Epidemiological research Epidemiolo
Page 197 and 198: data from cancer registries. In the
Page 199 and 200: The importance of cancer registries
Page 201 and 202: Ess Silvia | Patterns of care and s
Page 203 and 204: Epidemiological research List of ap
Page 205 and 206: Impact This work will serve as the
Page 207 and 208: Thürlimann Beat | Management of br
show all

Cancer Research in Switzerland - Krebsliga Schweiz

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?